ISOQUERCETIN

It is suggested that isoquercetin suppressed reactive oxygen species (ROS) and Lactate dehydrogenase (LDH) release in hippocampal neurons, via the regulation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2‑mediated) nuclear factor erythroid 2‑related factor 2 (Nrf2)  expression, which may provide a useful strategy for the moderation of neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. It acts as a selective SIRT6 activator since it only binds to the SIRT6-selective acyl binding channel through its ability to distinguish between the SIRT6-selective acyl binding channel and an alternative binding site at the entrance of the active binding site of SIRT6. Furthermore, an isoform selectivity study of isoquercetin revealed that the bulky sugar moiety accommodates SIRT6’s acyl channel. Isoquercetin has been reported to exert its cytotoxic/anticancer activity by inhibiting protein kinase B phopsphorylation, and thus surviving protein activates caspases and reduces anti-apoptotic proteins, i.e., Bcl-2 and Mcl-1.

PUBLISHED ARTICLES :

** Exp Ther Med. 2017 Apr;13(4):1353-1359.doi: 10.3892/etm.2017.4093. Epub 2017 Jan 31.

Isoquercetin activates the ERK1/2-Nrf2 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro

** Cell J. 2021 Aug;23(3):355-365.doi: 10.22074/cellj.2021.7116. Epub 2021 Jul 17.

Neuroprotective Effects of Isoquercetin: An In Vitro and In Vivo Study

** Eur Rev Med Pharmacol Sci. 2022 Dec;26(23):8700-8712.doi: 10.26355/eurrev_202212_30541.

Effect of quercetin glycosides on cognitive functions and cerebral blood flow: a randomized, double-blind, and placebo-controlled study

** Int J Mol Sci. 2021 Apr 17;22(8):4180.doi: 10.3390/ijms22084180.

A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer's Disease, Aging, Cancer, Inflammation, and Diabetes